Moderna has been producing life changing vaccines since 2010, focusing on RNA and mRNA therapeutics. But recent events have made the company a household name worldwide.
Moderna was instrumental in Operation Warp Speed, the programme which accelerated the development of the COVID-19 vaccine. After its development in early 2020, Moderna went on to produce over 300 million doses of its mRNA vaccine.
But while many may know this side of the story, the company’s pioneering use of AI technology should garner much more attention.
Moderna’s visionary belief in AI, even above that of many of its innovative competitors, has undoubtedly fuelled its success. The company has led the way in viewing mRNA as a drug, leveraging its power to produce proteins and fight disease and infection.
In a world where AI-powered biotechs will drive the future of medicine, Moderna’s position as an early adopter is already seeing them take a definitive lead over their competitors.
And while the success of the vaccine programme is in the rollout of a lifesaving treatment to millions around the world, on the business front, it’s worth mentioning that Moderna reported USD 18.4bn in vaccine sales in 2022 with projections of USD 5bn for 2023.
